Authors

• Ivana Crnojević — Karlovac General Hospital, Karlovac, Croatia — ORCID: 0009-0007-7300-9865
• Iva Zec — Zabok General Hospital and Hospital of Croatian Veterans, Zabok, Croatia — ORCID: 0000-0002-7947-3577
• Ivo Darko Gabrić — University Hospital Centre“Sestre Milosrdnice”, Zagreb, Croatia — ORCID: 0000-0003-4719-4634
• Matias Trbušić — University Hospital Centre“Sestre Milosrdnice”, Zagreb, Croatia — ORCID: 0000-0001-9428-454X
• Ozren Vinter — University Hospital Centre“Sestre Milosrdnice”, Zagreb, Croatia — ORCID: 0000-0002-4236-7594
• Krešimir Kordić — University Hospital Centre“Sestre Milosrdnice”, Zagreb, Croatia — ORCID: 0000-0002-9707-6946
• Marko Boban — University Hospital Centre“Sestre Milosrdnice”, Zagreb, Croatia — ORCID: 0000-0002-6129-575X

Keywords

breast cancer, cardiotoxicity, myocarditis

DOI

Full Text

**Introduction:** We present a case report of severe cardiotoxicity in patient treated with dual anti-HER therapy in a neoadjuvant protocol. **Case report:** 44-year-old patient, with no comorbidities, was diagnosed in June of 2022 with luminal B, HER 2 positive breast cancer. Neoadjuvant chemotherapy (ACdd protocol), followed by HER-2 dual blockade (transtuzumab and pertuzumab) with an addition of paclitaxel was admitted before planned surgical treatment. Echocardiogram, performed regularly during treatment, confirmed a normal ventricular function. One month after finishing neoadjuvant protocol (in February of 2023), patient was diagnosed with congestive heart failure due to severe left ventricular dysfunction and reduction in ejection fraction (EF, 15%). Optimal medical therapy was prescribed, and she was discharged home. In March 2023, she was admitted hospital for planned surgical operation, but since her symptoms did not improve, a worsening of left ventricular dysfunction was detected as well as pulmonary embolism, and she was transferred in Cardiac Intensive Care unit where inotropic and vasopressor therapy (dobutamine and norepinephrine) was initiated. Echocardiogram showed significantly reduced EF (15-20%). Additionally, NMR showed subepicardial and mesocardiac fibrosis suspicious for myocarditis. Myocardial biopsy was not performed, but regression in levels of troponin were accomplished with methylprednisolone admission. Since rhythmic instability, as well as NMR results and reduced systolic function (EF 35%), the patient received a subcutaneous ICD. Right breast segmentectomy and sentinel biopsy were performed after relative cardiac stabilization. The patient continued to be monitored in outpatient clinic and regular echocardiogram registered a slightly better EF, now about 40-45%. **Conclusion:** A significant issue arises in patients undergoing a neoadjuvant protocol when systemic oncological treatment is given prior to surgery. (1-3) In these patients, the emergence of significant cardiotoxicity impacts the timing of surgical intervention and, consequently, the prognosis of the malignant disease.

Literature

1. Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022 January 31;43(4):280–99. https://doi.org/10.1093/eurheartj/ehab674
2. Gabrić ID, Vazdar L, Pintarić H, Planinc D, Trbušić M, Jazvić M, et al. O146 Prediction of reversibility of cardiotoxicity caused by immunotherapy with trastuzumab. Glob Heart. 2014;9(1) Suppl:e40. https://doi.org/10.1016/j.gheart.2014.03.1355
3. van Kalsbeek RJ, Mulder RL, Skinner R, Kremer LCM. The Concept of Cancer Survivorship and Models for Long-Term Follow-Up. Front Horm Res. 2021;54:1–15. https://doi.org/10.1159/000514693